SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ALKS

Alkermes plc. (NASDAQ:ALKS)

Ireland · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - Specialty & Generic
$44.94-$1.24 (-2.69%)
 
Market cap
$7.55B
Insider Score
Analyst consensus
Market Cap$7.55B+59.4%
Revenue (ttm)$1.75B
Net Income-$351.00K
EPS-$0.01
Shares Out168.04M
PE Ration/a
Forward PE33.21
Dividendn/a
Ex-Dividend Daten/a
Volume1,080,735
Open$45.79
Previous Close$46.18
Day's Range$44.83 - $46.89
52-Week Range$27.00 - $55.67
Beta0.23
AnalystsBuy
Price Target$57.74(+28.48%)
Earnings DateNov 3, 2026

About ALKS

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Address
Connaught House, Dublin, D04 C5Y6, Ireland
Market Cap
7.55 billion
Employees
2,050
Industrial Classification
Drug Manufacturers - Specialty & Generic

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$5.66M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy1 Hold0 SellAvg target $60.25 (+34.1%)

5 firms rating ALKS in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-2.69%
5 Days
-4.44%
1 Month
+1.72%
6 Months
+22.12%
1 Year
+59.42%

$ALKS stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of ALKS by members of U.S. Congress

Gilbert CisnerosHouse / DPurchase$1.00K – $15.00KSep 29, 2026
Gilbert CisnerosHouse / DPurchase$15.00K – $50.00KJul 30, 2026
Gilbert Ray CisnerosHouse / DPurchase$15.00K – $50.00KJul 30, 2026
Gilbert Ray CisnerosHouse / DPurchase$15.00K – $50.00KJul 29, 2026

Recently reported changes in ALKS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ALKS's directors and management

Net Shares Purchased by Insiders−90k−45k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ALKS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ALKS Revenue by Segment

$834.56MTotal
Product sales, net$417.28M50.00%
VIVITROL$127.56M15.28%
ARISTADA and ARISTADA INITIO$103.90M12.45%
LYBALVI$95.90M11.49%
LUMRYZ$89.92M10.77%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ALKS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ALKS from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from ALKS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
84
News & Sentiment
20% of score
72

News check: CEO outlines six clinical readouts, LUMRYZ filing expected, and exclusivity extension for Lybalvi provide multiple near-term catalysts despite pricing headwind on Alixorexton.

Recent Insider Activity

Buys
0
Sells
16
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-42.0 since Aug 21
0255075100Aug 21 — Insider Score 42.0Aug 22 — Insider Score 42.0Aug 23 — Insider Score 42.0Aug 24 — Insider Score 42.0Aug 25 — Insider Score 42.0Aug 26 — Insider Score 42.0Aug 27 — Insider Score 42.0Aug 28 — Insider Score 42.0Aug 29 — Insider Score 42.0Aug 30 — Insider Score 42.0Aug 31 — Insider Score 42.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 28.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

MEDXHorizon Kinetics Medical ETF4.81%
IBRNiShares Neuroscience and Healthcare ETF4.75%
PSCHInvesco S&P SmallCap Health Care ETF4.23%
FBTFirst Trust NYSE Arca Biotechnology Index Fund3.78%
TYNEDirexion Nanotechnology ETF3.37%
SMCFThemes US Small Cap Cash Flow Champions ETF2.20%
XSMOInvesco S&P SmallCap Momentum ETF1.86%
TDNAT. Rowe Price Biotech ETF1.79%
XBIState Street SPDR S&P Biotech ETF1.55%
MNTLTema Neuroscience And Mental Health ETF1.53%
GSCGoldman Sachs Small Cap Equity ETF1.52%
FLQSFranklin U.S. Small Cap Multifactor Index ETF1.04%

Weight is the stock’s share of each fund’s holdings.